Intercept Announces Pricing of Public Offering of Common Stock By Selling
NEW YORK, Oct. 8, 2013
NEW YORK, Oct. 8, 2013 /PRNewswire/ --Intercept Pharmaceuticals, Inc.
(NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the
development and commercialization of novel bile acid therapeutics to treat
chronic liver diseases, today announced the pricing of an underwritten public
offering of 1,500,000 shares of its common stock by certain selling
stockholders at a public offering price of $62.50 per share. In addition, the
selling stockholders have granted the underwriters a 30-day option to purchase
up to an additional 225,000 shares of common stock.
All of the shares in the offering are to be sold by the selling stockholders.
Intercept will not receive any proceeds from the sale of the shares of common
stock by the selling stockholders in the offering. The offering is expected
to close on or about October 15, 2013, subject to customary closing
BofA Merrill Lynch is acting as the sole bookrunning manager and underwriter
for the offering.
A registration statement on Form S-1 relating to the shares of common stock
being sold in this offering was declared effective by the Securities and
Exchange Commission on October 8, 2013. A preliminary prospectus relating to
the offering has been filed with the SEC, and a final prospectus relating to
the offering will be filed with the SEC. Copies of the final prospectus, when
available, may be obtained from the offices of BofA Merrill Lynch, 222
Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry. The company's
lead product candidate, obeticholic acid (OCA), is a bile acid analog and
first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially
being developed for the second line treatment of primary biliary cirrhosis
(PBC) in patients with an inadequate response to, or who are unable to
tolerate, ursodiol, the only approved therapy for this indication. OCA has
received orphan drug designation in both the United States and Europe for the
treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and
China, where it has out-licensed the product candidate to Dainippon Sumitomo
For more information about Intercept, please contact Barbara Duncan or Senthil
Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000.
SOURCE Intercept Pharmaceuticals
Press spacebar to pause and continue. Press esc to stop.